Callio Therapeutics logo

Callio Therapeutics

calliotx.com

Callio Therapeutics develops dual-payload antibody-drug conjugates (ADCs) for people with cancer, including patients with tumors that have developed resistance to existing therapies. Its platform pairs synergistic drug payloads and uses a proprietary linker to design targeted treatments intended to overcome resistance and deliver more durable responses.

Facts

HQ
Seattle, WA, USA
Sectors
Biotechnology Research
Founded
2025
Employees
24
Stage
Series A

Is this your organization? Claim it

By Callio Therapeutics

People

See all 8
  • Jerome Boyd-Kirkup Co-Founder
  • Piers Ingram Co-Founder
  • Chris Hassig Executive, Chief Scientific Officer

Online

Questions about Callio Therapeutics

What is Callio Therapeutics?

calliotx.com

Who are the people behind Callio Therapeutics?

Seattle Flow lists Jerome Boyd-Kirkup (Co-Founder), Piers Ingram (Co-Founder), Chris Hassig (Executive, Chief Scientific Officer) and 5 more at Callio Therapeutics.

Who invested in Callio Therapeutics, and how much has it raised?

Members of Seattle Flow see Callio Therapeutics' funding rounds, amounts and investors on its Funding tab. Joining is free.

Where is Callio Therapeutics based?

Callio Therapeutics is headquartered in Seattle, WA, USA.

When was Callio Therapeutics founded?

Callio Therapeutics was founded in 2025.

How many people work at Callio Therapeutics?

Callio Therapeutics has 24 employees.